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4. Background and aims  
The Janus Serum Bank of Norway was established in 1973, and was dedicated to cancer 
research. It has been widely used to assess exposure and risk factors for development of 
cancer. The bank holds approximately 450.000 samples from more than 315.000 people 
that have been followed for development of cancer in the Cancer Registry of Norway, 
some of them for up to three decades. Today there are more than 48.000 (per December 
2008) incidents of invasive cancers in the bank. Biorepositories have become an important 
resource in cancer epidemiology. The scientific value of an epidemiological study may be 
significantly enhanced by analysis of putative cancer markers in biological specimens 
collected from the study population. Biomarkers can be classified as markers of exposure, 
disease or susceptibility. Quantifying a biomarker may give more reliable and valid 
information on exposure than records or self reported data. The value of a study based on 
archival serum samples may be threatened if there are variations in preanalytical sample 
handling, degradation, molecular modification or loss of water during storage. One of the 
most important aspects of biobank activities is to evaluate the quality of the samples. The 
knowledge of component stability is essential for the interpretation of a study based on 
historical samples.   
 
The use of archival samples generates some important question: Do we measure the most 
informative component? Are samples comparable when storage time differs with decades? 
Those and similar questions may be of high importance in the planning and interpretation 
of a study on archival serum samples. The overall aim of the thesis was to describe the 
quality of archival serum samples and discuss their usefulness in epidemiological studies.  
 
Specific aims of the papers: 
- To evaluate the impact of preanalytical sample handling, short- and long-term 
storage, and describe changes in selected biochemical serum components. 
- To investigate long-term stability of protein biomarkers. 
- To estimate recovery of folate in long-term stored serum samples. 
- To measure testosterone in archival serum samples and discuss sample stability,  
measuring methods and changes in the background population.  
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5. Introduction   
Epidemiology is a fundamental medical discipline that focuses on the distribution and 
determinants of disease in a human population. Classic epidemiologic studies use 
observations, register records, reports, and interviews to assess risk factors of a disease. 
Studies based on biomarkers of exposure, effect or susceptibility may greatly improve our 
understanding of host factors and environmental influence. Analysis of biochemical 
samples can also be used to control for confounding factors, or to evaluate the effect of 
bias.  
Cancer epidemiology may focus on causes and precursors of the illness. Cancer is a 
disease that often occurs late in life and may take years to develop. The use of archival 
serum samples can offer a great opportunity to investigate the relationship between 
exposure and disease or detect early signs in the carcinogenic process. 
A biobank is defined as a systematic collection of human biological samples, prepared and 
stored for later use and commonly linked to demographical and clinical data. Samples of 
body fluids or tissues are the most common material.  
The potential value of a biobank depends on the quality of the samples, i.e. to what extent 
they may reflect the biological, or biochemical situation in the individual at the time of 
sample collection. Variation in sampling and storage conditions (i.e. temperature, 
environmental humidity, light exposure, and type of vials and caps) may be crucial for the 
sample quality. Both component and even the analytical methods may exhibit diverse 
robustness against such variations and therefore component instability has the potential to 
invalidate research results. 
 
5.1 Serum  
Circulating blood consists of blood cells and blood plasma comprising approximately 45% 
and 55%, respectively. Plasma consists of about 90% water, where many components are 
kept in solution: proteins (i.e. immunoglobulins, transport proteins, enzymes), lipids, 
hormones, vitamins, minerals, salts and ions, amino acids, water soluble components, 
inorganic electrolytes, sugar, carbon dioxide and oxygen. Plasma is separated from a 
blood sample to which an anticoagulant (EDTA, heparin or citrate) is added. Serum is 
obtained after coagulation, and in contrast to plasma does not contain fibrinogen. A blood 
sample in a glass tube will clot after ½-1 hour if no anticoagulant has been added. 
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Erythrocytes and leucocytes are trapped in the clot separating them from serum. Figure 1. 
shows the difference between plasma and serum.  
 
 
 
Figure1. Illustration of the components in plasma and serum                                                                            
 
5.2 The Janus Serum Bank   
The Janus Serum Bank was established in 1973 by the pathologist Olav Torgersen (1907-
1978) with funding from the Norwegian Cancer Society. The biobank was dedicated to 
cancer research and was named after the two-faced Roman God, Janus, to symbolize the 
possibility for combined prospective and retrospective studies of disease. The idea was to 
store serum from healthy persons for identification of early markers in those who later 
were found to developed cancer. The Janus Serum Bank was made possible by a huge 
voluntary collaborative effort in Norway. The funding gave room only for simple practical 
and logistics solutions with respect to temperature monitoring, sample access etc. Despite 
these limitations and a suboptimal temperature of –25 ºC, the bank has been used 
extensively. The Janus Serum Bank was launched at a time when hardly anyone fully 
understood the value of creating such a type of specimen collection. The biobank contains 
serum samples from the early 1970s onwards, from a time when the diet had higher fatty 
content, when anti-tobacco work was in its early infancy, and environmental contaminants 
like PCB and DDT had not yet been banned. The bank is population-based and covers 17 
of the 19 counties in Norway, not including Hordaland and Buskerud. Some 90% of the 
samples came from people in their forties undergoing health surveys of cardiovascular 
disease risk. The rest have been collected from the Red Cross Blood Bank donors in and 
Plasma Serum 
Blood clot with RBCs, 
WBCs and platelets  
RBCs 
WBCs and platelets 
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around Oslo, many of whom have given samples to the bank repeatedly (1). The collection 
of samples was terminated in 2004 except for previous Janus donors, hospitalized with a 
cancer diagnosis at The Radium Hospital in Oslo. The donors in the health examination 
cohort were largely 39–45 years old at retrieval while the blood donors were 18–65 years 
old. During 36 years of sample collection, the serum bank reached approximately 450.000 
samples in 1 to 5 aliquots from more than 315.000 donors (per 2009). Apart from the high 
numbers of sera with a follow-up time of up to 35 years, the probably greatest benefits of 
the Janus Serum Bank are the possibility of linkage to a national high-quality cancer 
registry, a public registry for vital status and a public health institute for health 
information. The bank is one of few in a world scale referring to age, follow-up time and 
number of cancer cases. The donors in the Janus Serum Bank have given informed 
consent for the use of their samples in cancer research, mandatory by laws and regulation 
of personal secrecy according to requirements at the time of blood draw. 
 
5.3 The sample collections and routines 
5.3.1. Health examination samples                                                                                                                  
The first health examinations were carried out in Oslo in the period 1972–73 and included 
17.400 men. In the period 1974–78 health examinations were performed in Finnmark, 
Sogn og Fjordane, and Oppland and comprised 54.800 men and women. In the period 
1980–91 the health examinations among people in their 40s were performed across the 
country, and samples from about 238.000 individuals were added to the bank. The 
examinations were all subjected to cardiovascular disease and risk factors. In 2002 an 
examination on health and life condition in Troms was launched. The Janus Serum Bank 
received samples from 4.900 individuals from this survey. 
During the enrolment in 1974–78, all samples were collected in Vacutainer™ 10 ml tubes 
containing 5 mg of sodium iodoacetate as a preservative for glucose (2). From 1978 till 
1986, the samples were collected in plain tubes without additives, while the samples from 
the later years were collected on gel vials. After coagulation in room temperature and 
centrifugation, the serum was either transferred to new vials (glass or poly propylene 
tubes) before shipment, or transported on gel tubes to Ullevål Hospital in Oslo. The 
samples were sent, in batches of 200–300 in specially constructed cooling containers 
securing a temperature between +1 ºC and +10 ºC, and reached the laboratory 45–60 hours 
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after collection (2). The samples were analysed for cholesterol and triglycerides. The 
Janus Serum Bank received rest volume (0.5–2.0 ml) after the analyses. Depending on 
transport distance to Oslo, the analysing and subsequently freezing of the serum samples 
for the Janus Serum Bank could be delayed for days. Blood sampling was done at any 
time of the day between 8 am and 6 pm when the subject showed up without requirements 
of fasting. A majority of women appeared early in day-time while men mainly arrived in 
the afternoon.  
 
5.3.2 Red Cross blood donor samples 
The sampling routine of blood donors has followed standard routines during the years. 
Samples were collected at daytime between 8 am and 6 pm. The donors were non-fasting 
and blood was drawn with the donor in a supine position. The tubes carried no additives or 
separating gel and were coagulated in room temperature and stored at +4 °C over night 
before transport to the Janus Serum Bank. The clotting time could vary between14 – 28 
hours. After centrifugation the serum was transferred to new vials before freezing. The 
serum was stored in 5 ml polypropylene tubes. Samples collected in 1973–75 (about 7000 
vials) were lyophilized and have to be rehydrated before use. In the time period 1973–91, 
a blood donor gave a sample of 50 ml for the Janus Serum Bank. In the period 1997–2005 
the volume was reduced to 20 ml.  
 
5.3.3 Post diagnostic samples     
Today a Janus donor, who is hospitalized at the Radium Hospital, will by admission be 
asked to give a sample to the Janus Serum Bank before treatment is started. The samples 
are collected in tubes without additives. After coagulation in room temperature and 
centrifugation the serum is transferred to polypropylene tubes and frozen. 
All samples in the Janus Serum Bank have been stored in paper boxes covered with lids in 
a commercial freezer department. Exposure to light has only occurred during collecting, 
retrieval, thawing, and aliqouting of samples. 
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5.4 The Cancer Registry and linkages to Janus    
In 2004, the Janus Serum Bank was transferred from The Norwegian Cancer Society to 
the Cancer Registry of Norway (CRN). CRN was founded in 1951 and has registered 
virtually all new cancer cases in Norway since 1953. Reporting cancer cases is mandatory, 
and the information comes from several independent sources, like pathology laboratories, 
hospitals, the national patients discharge registry and causes of death registry, thus 
securing a high grade of completeness. The quality of CRN has recently been evaluated as 
high (3-5). For administrative purposes, personal identification numbers (PID) have been 
assigned to all Norwegian residents alive in 1960 or born later. All registration of cancer is 
linked to the PID. The samples in the Janus Serum Bank are either labelled with the PID 
or a registration number that are linked to the PID. The PID ensures the possibility of 
identifying new cancer cases in the Janus Serum Bank. The Janus cohort is regularly 
linked to the cancer registry for update with incident cases. Presently, the cohort contains 
more than 48.000 cases of invasive cancer (per December 2009). The Cancer Registry 
holds the licence and has been the data handler for the Janus Serum Bank from the start. 
One of the important research goals of the cancer Registry is to set up testable 
biologically-founded hypotheses, using biological markers of exposures, and collaboration 
with researchers in the relevant fields. Specifically this will include utilisation of Janus 
Serum Bank (6).The linkage between registries with reliable data, especially concerning 
cancer incidence, mortality, health, lifestyle, and biological samples from a considerable 
number of individuals offer an extremely large study base for research. A paper on quality 
aspects in studies linking cancer registries and biobanks with experiences from Janus and 
other Nordic biobanks has recently been published (7). Linkages between the Janus Serum 
Bank and CRN have been used for more than 65 publications (8) from a number of 
research groups. The Janus Serum Bank has participated in several international 
collaborative studies based on linkages of large population-based biobanks and cancer 
registries (9). Nordic Biological Specimen Banks working group on Cancer Causes & 
Control (NBSBCCC) is a network consisting of 16 biobanks and 5 cancer registries. 
Cancer Control using Population-based Registries and Biobanks (CCPRB) is a network 
project within the sixth framework programme of the European Union involving 20 
biobanks and 7 cancer registries located in 9 European countries. The intention of the 
networks has been to provide biological and statistical resources for etiological studies of 
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cancer, focusing on longitudinal studies and large-scale research for genetic and infectious 
causes of cancer. The present thesis has been performed within this network collaboration.  
  
5.5 Sample stability 
Stability can be described as the tendency of a component of a system to withstand 
changes and retain the initial property of a measured analyte for a period of time when the 
sample is stored under defined conditions (10). The aim of a clinical laboratory test is to 
measure the concentration or activity of a constituent in a body fluid or tissue in order to 
give information relevant to the clinical state of a patient. To give a correct or valid result, 
the composition of the samples for analysis should not change during the preanalytical 
phase, or at least one should have some information about the change (11). The primary 
sample, i.e. full blood, usually remains for short time (hours) at room temperature (20 to 
25 °C) or at +4 °C while the secondary sample, i.e. serum/plasma, is kept between +4 °C 
and –196 °C for days, months or years. In the Janus Serum Bank, the primary samples 
have been kept at +4 °C for up to 28 hours and the secondary samples have been stored at 
–25 °C, some of them more than three decades. 
 
The degree of stability of a blood constituent during the preanalytical phase can be 
influenced by a number of factors. As time and temperature have a major influence, one 
could determine a maximum permissible storage time with defined conditions, under 
which the quality may be satisfactory. The degree of stability can be described by the 
absolute difference, or by the ratio (percentage deviation) of results achieved from 
measurement at time zero and after a given period of time. 
 
5.6 Factors affecting the outcome of component measurement 
Serum components show biological variation, and several factors in the preanalytical, 
analytical and post-analytical phase may lead to additional variations in test results. Most 
measurements errors are due to preanalytical factors, while a high error rate has also been 
found in the postanalytical phase (12). In a study of types and frequency of mistakes in a 
laboratory, Plebani et al. (13) reported the following distribution of the source of mistakes: 
68% preanalytical, 13% analytical and 19% postanalytical. Figure 2 presents factors that 
are affecting the different phases. 
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Preanalytical                                                                                                              
phase 
 
 
  
   
 
 
  
                                                                                                          
 
Analytical                                                                                                                    
phase 
 
 
 
Postanalytical                                                                                                            
phase 
Pre-freezing factors                                                                                
Clotting time and centrifugation, light exposure, type of vials and 
caps, time and temperature until freezing 
Reporting of results                                                               
Interpretation                                                                                                
Methods                                                                                                        
Analytical variance, accuracy and precision 
Sample preparation                                                                               
Thawing                                                                                                              
Sample matrix                                                                                        
Bias, methods can be influenced by hemoglobin, bilirubin, lipids, 
paraproteins and drugs  
Sample-collection                                                                             
Timing, diurnal and annual variation  
Transport                                                                                   
Temperature and time during transport 
Retrieval, aliquoting samples                                                                         
Light exposure, temperature and time before refreezing
Biological variation                                                                               
Body posture, psychological and physiological stress during blood 
draw, diet, exercise, use of alcohol, coffee, drugs, smoking, etc 
Storage                                                                                             
Temperature, loss of water, degradation, changes in component 
structure  
 
Figure 2. Factors that may affect the measurement of a biobank sample in the different 
analytical phases 
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5.6.1 Biological variation                                                                                                            
Laboratory test results from the same individual may vary according to diurnal or 
biological rhythms over time. Some serum components may change from infancy 
throughout life, and it is necessary to stratify according to age. The level of an analyte 
may also have biological cycles or rhythms. Diurnal biological rhythm is well described 
for some hormones (e.g. cortisol, growth hormone, testosterone), and the monthly cycle of 
women in fertile age is of major importance in laboratory medicine (14). There is less 
documentation on seasonal cycles, although vitamin D has shown seasonal variation in 
serum level correlated to sun exposure (15).     
 
5.6.2 The preanalytical phase  
In general the impact of preanalytical factors is difficult to estimate due to high number of 
potential influencing sources. A detailed standard operation procedure (SOP) is therefore 
necessary to secure the quality in this phase. The preanalytical factors may be of technical 
or biological type. When information on technical sample handling is limited, some 
information may be drawn from analysing serum components known to be affected by 
non-optimal treatment. For instance, analysing potassium may provide information on 
clotting time and storage before freezing due to leakage of the component from the red 
blood cells (11;16). Light exposure will decrease the bilirubin concentration in a sample 
(11) and signs of haemolysis can indicate improper sampling or processing. 
During long-term storage, the main threats against sample quality are degradation, loss of 
water, molecular modification, and conformational changes in protein structures.  
Choosing the best vials and caps for long-term storage is important. Polyethylene test 
tubes with screw tops are recommended to prevent desiccation(17). Sodium is an element 
whose serum concentration is rather insensitive to preanalytical factors and is not 
subjected to degradation during storage. Measurement of this element may therefore 
provide information on water sublimation in the vials. 
Earlier studies (18-21) have addressed short-term stability at different temperatures (–20 
ºC and up to +3 ºC)  for different components in serum, but there are limited data for 
storage temperature of –25 °C and storage time exceeding more than a few years.  
Generally, the primary structure of proteins seems to tolerate long-term storage at –25 ºC 
(22) and immunoglobulins (IgE) have been proven stable at –20 ºC for up to 37 years 
(23;24). In contrast, proteins that are dependent of  3-dimensional structure to retain their 
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biological function (enzymes), a characteristic often used for measurement, are more 
fragile (25-27). Enzyme activity can be used as a measure of the quality of the active 
enzyme present. Dissociation of subunits in enzymes may decrease the activity (28). Some 
vitamins are very stable (vitamin A and vitamin D) for years (29;30) while Voogd et al. 
(31) reported substantial degradation (39%) of folate by two years of storage at –20 ºC.  
Thawing and refreezing may be necessary for the preparation of aliquots for laboratory 
analyses. It is generally regarded that fast freezing of the sera is the optimal treatment 
although this may not be the case for proteins. Cao et al. (32) have reported that slow 
freezing about 1 ºC/min and fast thawing at a rate >10 ºC/min give higher activity 
recovery whereas fast refreezing with slow thawing resulted in more severe damage to the 
proteins. Cecchini et al. (33) suggested that protein degradation is not caused by repeated 
freeze thaw cycles but rather by long storage in room temperature, and they therefore 
recommended fast refreezing.  
Repeated refreezing and thawing of sera may be thought of as harmful for the sample 
quality. There is, however, information from a number of studies showing that several 
refreezing and thawing cycles do not alter assay results for many serum components. 
Experiments of 5–12 repeated freeze thaw cycles have shown that the serum levels 
remained stable for constituents like electrolytes, enzymes, protein (34), general hormones 
(35), female reproductive hormones (36), some biomarkers (37), and some tumour 
markers (34;38). However, lipoproteins and some enzymes were significantly reduced 
(39;40), and SHBG was reduced 3.3% per cycle (36). 
 
5.6.3 Analytical phase 
An accurate outcome of a component measurement is dependent of correct analytical 
procedure, including optimal instrumentation, and use of quality controls to detect errors. 
In this phase, errors may be identified by using strict quality criteria for the assays. The 
quality of the analysis can be described quantitatively by precision and trueness which 
refer to the results of repeated measurements. Accuracy reflects how the two former 
properties affect one single measurement.  
Precision is the closeness of agreement between independent test results of the same 
sample obtained under specified condition (41). The coefficient of variation (CV) is a 
dimensionless measure of precision and is defined as the ratio of the standard deviation s 
to the mean X : CV = Xs   
17 
 
It describes the degree of random errors and is useful for comparison of data sets with 
different units or extensively different means. Trueness is defined as the closeness of 
agreement between the average value obtained from a large series of test results, and an 
accepted reference or consensus value. An often used indicator of trueness is  
bias = (mean value-true value)/(true value) (41). Bias is an expression of systematic errors. 
Accuracy of measurement is described as the closeness of agreement between one single 
measurement of a quantity and the true value of the measured component. Accuracy thus 
embraces the concepts of both precision and trueness, and represents the sum of random 
and systematic errors (total error).  
 
Another analytical property that may affect the results is the so-called analytical 
specificity that refers to the ability of an assay to measure the component it claims to 
measure, free from interference by any other element or compound. In biochemical 
analysis, the matrix refers to the components of a specimen other than the analyte. The 
matrix may have substantial effect on the way the analysis is carried out and the quality of 
the results obtained; such effects are called matrix effects. There are four major 
endogenous matrix compounds that often interfere with laboratory analysis: haemoglobin, 
bilirubin, lipids and paraproteins. The major exogenous sources of interference are drugs, 
diagnostica, food constituents or sample additives (42).   
 
Quality requirements                                                                                                                   
A recommended criterion for analytical imprecision is CVa< 1/2·CVw (Cotlove’s criterion) 
(43) where CVa is the analytical coefficient of variation and CVw is coefficient of variation 
within individual. This ensures that the variation within an individual can be monitored 
with an acceptable degree of precision, and the underlying data are obtained from repeated 
sampling from presumably healthy persons. Reference values provide a tool for 
interpretation of laboratory data. The reference interval embraces the total biological 
variance in a reference population, presumably healthy individuals, including the 
analytical imprecision (44). The total biological variance of a component in a given 
population consists of fluctuation around the homeostatic balance within the individuals 
(w) and between individuals or groups (g). The corresponding coefficient of variation is 
given by the following expression: 
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 22 gw CVCV           [1] 
Including the analytical variation CVa, the CVref for the measurements in a reference 
population is: 
CVref ≈  222 agw CVCVCV        [2] 
given that the variations are normally distributed. 
Assuming good laboratory practice, analytical variance represents random errors in the 
method, and is for many components small compared to CVw and CVg. Total biological 
variance will therefore largely determine the reference limits. Data on the biological 
variability in presumably healthy individuals have been published (14;45). 
A difference in mean serum component level between two populations may be found 
statistically significant, however not all statistically significant differences are of 
biologically importance. A separate criterion has been developed to evaluate the biological 
relevance of an observed bias (45).  
An often used quality criterion for the acceptable bias is: 
|Bias|max ≤ 1/4 · total biological variation= 1/4 22 gw CVCV         [3] 
This criterion secures that the reference interval and hence also the localization of the 
study population are not substantial changed from its true value. 
In situations where the separate components in [2] are unknown, an alternative formula is 
used: 
|Bias|max < 1/4·CVref = 1/16 · (upper reference limit-lower reference limit)       [4] 
since the width of the reference interval is 2· (1.96· SDref) ≈ 4 SDref    
When comparing methods where the exact trueness of either of them is not known, an 
alternative bias criterion has been proposed:   
|Bias|max < 3
wCV (46)               [5] 
 
 
5.6.4 Postanalytical phase  
Report errors may be difficult to assess due to automation of analytical process and 
computer controlled systems. An irregular measurement will often be checked by a new 
analysis of the sample, but incorrect results within the reference interval may be accepted 
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more easily. In order to avoid this type of error, quality control systems should be 
implemented. Testing for changes from previous results (delta checks) is one possibility. 
Many clinical laboratories provide a fixed commentary associated with a particular test 
result, but correct interpretation also requires clinical data in addition of the patient’s age 
and sex. Time of sampling and the patient status concerning diet, lifestyle, and factors that 
influence biological variations should also be taken in to consideration.  
 
5.6.5 Total measurement uncertainties 
Usually measurement uncertainties are considered to be a problem in the analytical phase. 
Kouri et al. (47) have established an uncertainty concept that take into account the patient 
(biological variation), the sample (handling, storage) and the analytical variation (assay). 
The concept is meant to assist the interpretation of laboratory results. A measurement 
uncertainty estimate may be important for evaluation of the confidence in a single 
measured value. In this work we have compared groups and described the sources of 
variation, but we have not numerically calculated the uncertainties of the different phases. 
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6. Material and methods 
 
6.1 Material 
The biological material in these studies was retrieved from the Janus Serum Bank. The 
samples were selected among male blood donors aged 40–49 collected in 1979, 1991, 
2002, 2004, and 2008. Table 1 shows the distribution of samples, sampling years, storage 
time, and age in the different papers. In paper I and II the samples were analysed in 2004, 
while in paper III and IV the samples were analysed in 2008. All samples were retrieved, 
thawed in room temperature, and aliqouted before fast refreezing on dry ice.  
  
Table 1. Description of material, storage time and age groups used in paper I-IV 
  Paper I and II Paper III Paper IV 
Number of 
Samples 
390 650 520 
Sampling years 1979, 2002 and 
2004 
1979, 1991, 2002, 
2004 and 2008 
1979, 1991, 2004 and 
2008 
Storage time 25, 2 and 0 years 29, 17, 6, 4 and 0 
years 
29, 17, 4 and 0 years 
Age 40–49 40–49 40-49 
 
 
6.2 Design                                                                                                                                  
A cross-sectional design was used with groups of individuals from each year of blood 
draw. The groups consisted of 130 subjects of the same gender, age, and category (blood 
donors), and they were compared to estimate the impact of preanalytical sample handling, 
storage, use of different analysing methods, and potential lifestyle changes in the 
background population. The comparisons were based on mean value, median value, 
variance, and reference limits. 
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Ideally, for a stability study on archival serum samples, one would like to have access to 
identical samples retrieved from the same individuals at the same point of time, stored for 
different time intervals, and still have the opportunity to analyse them simultaneously with 
the same methods and instruments. This is clearly not possible. The two potential outlines 
for a stability study would then be repeated cross-sectional design and longitudinal time 
series design.  
 
In the absence of historically planned longitudinal series, a cross-sectional design was 
chosen. Time points were selected to cover short and long-term storage. For the first study 
(paper I-II), we choose samples from 2004, 2002, and 1979. The analyses were performed 
in 2004, giving storage times of 0, 2, and 25 years. At the end of 1979, more than half of 
the blood donor samples in the Janus Serum Bank had been collected. This year was 
therefore selected as the earliest time point. In the second study (paper III), we compared 5 
time points: 2008, 2004, 2002, 1991, and 1979. The analyses were performed in 2008 
giving storage time of 0, 4, 6, 17, and 29 years, respectively. Folate measured by routine 
methods shows substantial degradation already after a few months of storage. More time 
points were therefore chosen to be able to assess the degrading process in larger detail. In 
the last study (paper IV), the time points 2008, 2004, 1991 and 1979 were selected giving 
storage time of 0, 4, 17 and 29 years. 
 
The selection of individuals was random among eligible blood donors that fulfilled the 
requirements (sex, age, and collecting year). The blood donors constitute a subgroup in the 
biobank (10%) and may not be representative for all donors in the bank. Nevertheless, the 
use of samples from blood donors for stability studies may be justified by the fact that our 
question of interest was potential changes in the stored samples over time, and not the 
occurrence of disease in a representative population. In contrast to patient material, the 
blood donor group will have low prevalence of pathological laboratory results. Our age 
requirements were 40-49 years, and men were selected to avoid potential interference 
from fluctuating fertility hormones. The majority of male donors in the bank were in their 
forties when they donated blood, and they were therefore a suitable age group.  
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6.3 Biochemical analyses                                                                                                          
In paper I, the selected components covered electrolytes (sodium, potassium and calcium), 
minerals (iron), and water-soluble molecules (creatinine, bilirubin and uric acid). These 
components were chosen to illustrate the impact of factors in preanalytical sample 
handling such as sublimation (sodium), clotting time (potassium), and light exposure 
(bilirubin). Creatinine is a marker of glomerular filtration rate (GFR) and may be used for 
correction of reference limits calculated for other components that may be retained when 
GFR decreases. The rest of the components were chosen to demonstrate component 
degradation or modifications, and matrix changes. 
The components in paper II were selected proteins of different types and structure and 
included immunoglobulins, carrier proteins and enzymes (ALT, AST, CK, albumin, 
ferritin, transferrin, SHBG, IgE, IgG, and C-peptide). Most biomarkers investigated in the 
Janus Serum Bank have been proteins, and therefore knowledge of protein stability is 
highly relevant. Immunoglobulins have been widely analysed in cancer projects and were 
consequently an obvious choice. Components in paper I and II have been analysed by 
different assays: colorimetric, enzymatic, immuno electrochemiluminescence, immune 
fluorometric, immunturbidimetric, and ion selective electrode.  
 
Paper III focused on different methods for measuring folate and folate catabolites. Some 
other components (homocystein, methyl malonic acid, and vitamin B12) known to reflect 
folate status were also measured. Impaired folate status has been associated with different 
forms of cancer (48), and has been used as a biomarker in epidemiological biobank 
studies. It has not been possible to get reliable folate measurements from archival serum 
samples mainly due to folate instability and methods offering low recovery. Three assays 
were compared 1) liquid chromatography separation followed by a tandem mass 
spectrometry (LC-MSMS) measuring circulating folate and oxidation products, 2) a 
microbiological assay measuring biological active folate, and 3) a new LC-MSMS assay 
using P-aminobenzoylglutamate (pABG) equivalents as a marker of total folate.  
 
The last paper (paper IV) investigated testosterone and components connected to the 
testosterone level in serum (FSH, LH, albumin, and SHBG). Measured values of 
testosterone depend on standardization, matrix effects, and cross-reactivity to other steroid 
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compounds of the method used. We compared two methods: a chemiluminescence 
immunoassay (IMM), and a LC-MSMS method. 
The serum components in paper I, II and IV were analysed at The Department of Medical 
Biochemistry, Rikshospitalet, Oslo University Hospital. The analyses were performed in a 
hospital routine laboratory using automatically analysing instruments known to minimize 
most of the random errors which may be of importance when studying sample stability. 
Most of the methods were accredited according to the Norwegian Standard NS-EN 
ISO/IEC 17025. The accreditation body, Norwegian Accreditation, perform technical 
inspection according to international rules for good laboratory practice. Testosterone was 
additionally analysed at St. Olav Hospital in Trondheim by a new LC-MSMS method. 
The components in paper III and cotinine levels in paper IV were analysed at Bevital 
laboratory, Bergen. This is a commercial laboratory offering non-routine analyses. Folate 
was measured with three different methods. The analyses have been conducted with large 
automatic analysing platforms.  
 
Samples from the different collecting time were merged and arranged in random adjacent 
positions in the same series to avoid bias from inter–assay variance. 
 
 
6.4 Statistical analysis 
To visualise the distribution form, z-score plots was used. Some of the component values 
were transformed (i.e. log or root) to achieve an approximately linear central part of the         
z-score plot. We applied Tukey’s fence (49) for exclusion of outliers which is necessary 
when performing parametric tests (ANOVAs and F-test). Analysis of variance (ANOVAs) 
was used to identify statistical significant group differences. To test for possible 
heterogeneity in degradation in the groups, the variance ratio test was used. Given that 
there were more than two groups to compare, a Student-Neuman-Keul post hoc test was 
used to identify the localization of group difference. In the comparison of mean levels 
between the groups in the studies, the referance group (0 Year) has been regarded as the 
true value for the level of components. The bias criteria based on biological variation 
|Bias|max ≤ 1/4 22 gw CVCV  gave the limit for what was an acceptable deviation between 
the compared groups. The bias criterion derived from the width of reference interval  
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|Bias|max < 1/4·CVref = 1/16 · (upper reference limit-lower reference limit) were calculated 
according to the RefVal method outlined in Tietz (44), and was used to control any 
systematic deviation from established reference limits. Comparison between methods was 
evaluated by a bias criterion  based on the coefficient of variation within individuals 
|Bias|max < 3
wCV . Both the statistical and biological significances of the distribution mean 
difference were evaluated, the latter established with bias criterion based on biological 
variation in presumably healthy individuals (45). Linear regression was used to estimate 
the change in component concentration per year and a Deming regression was used to 
compare two methods. A significance level of 5% was chosen except for the F-tests in 
paper III were Bonferroni correction yielded significance level of 5%/3=1.7%.  
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7.  Brief summary of results 
7.1 Paper I   
Long-term stability of serum components in the Janus Serum Bank                                                          
In order to investigate preanalytical sample handling we assessed the long-term (25 years) 
and short-term (2 years) stability of seven biological components in serum samples stored 
at –25 °C. Specimens from male donors, 130 in each group, stored for 25 and 2 years, 
were compared with 130 one-month-old samples. The distributions, dispersions, medians, 
means, and established reference intervals were used for comparisons. A significant 
difference in sodium of +3.9% in long-term stored serum samples demonstrated a small 
degree of sublimation during storage. In the 2 year-old samples an increased level of 
potassium (+19.9%) was interpreted as the influence of prolonged clotting time. The 
altered level of bilirubin (–32.4%) illustrated the effect of light exposure during 
preanalytical sample-handling. The differences for calcium and iron which should be as 
inert substance as sodium, did not reach statistically significance probably due to greater 
variation (analytical and biological).   
 
7.2 Paper II  
Stability of selected serum proteins after long-term storage in the Janus Serum Bank                            
The stability of selected proteins; immunoglobulins, carrier proteins and enzymes in 
samples stored at –25 °C were investigated. Three groups of 130 male samples stored for 
25 years (long-term), 2 years (short-term), and 1-month-old samples, respectively, were 
compared. The distribution of the values was examined, dispersion and localization of 
central tendency were compared, and reference intervals for each component were 
established. Albumin, AST, cystatin C, IgE, IgG, SHBG, and transferrin showed non-
significant or numerically small group differences. Large differences after 2 years of 
storage was seen for ferritin (–18.5%), ALT (–41.1%), CK (–41.1%), while insulin C-
peptide nearly totally decayed after long-term storage (–98.7%). The study demonstrated 
that immunoglobulins, which are often analysed in the Janus Serum Bank, are relatively 
robust to long-term storage. Enzymes, where alteration in the 3-dimensional structure or 
modifications that affect the catalytic site of the enzyme, may be critical for their 
properties and function, appeared to be more fragile. 
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7.3 Paper III   
Analytical Recovery of Degraded Folate in Archival Serum Samples                                                        
Folate status is often addressed in association with cancer. Measurement of folates in 
archival serum samples has proved difficult due to degradation during storage. Analyses 
that include degradation products may improve the results compared to routine 
immunological methods. We determined folate in human serum stored at –25 °C for 0, 4, 
6, 17, and 29 years by three different folate assays: 1) a microbiological assay, 2) a LC-
MSMS assay that measures different folate species, including 5-methyltetrahydrofolate 
(5mTHF) and the oxidation product 4-alpha-hydroxy-5-methyltetrahydrofolate (hmTHF), 
and 3) an assay that converts folate species to p-aminobenzoylglutamate (pABG), which is 
then quantified by LC-MSMS.  Although the loss of folate measured by the folate LC-
MSMS assay was less than for the microbiological assay, it was still substantial. The study 
showed a recovery of 41.3, 55.7 and 78.9% for folate determined by microbiological 
assay, LC-MSMS assay and as pABG equivalents, respectively. For assessment of the 
anticipated initial level, folate determined as pABG equivalents gave the most reliable 
result. 
 
7.4 Paper IV 
Stability of testosterone level in archival serum samples – methodological 
approaches, and changes in the background population                                                                              
The association between low hormone levels and impaired health status like the metabolic 
syndrome and cancer make measurement of testosterone important in epidemiological 
studies. Standardization, matrix effects, and cross-reactivity to other steroid compounds 
are of importance for the method used. Testosterone was measured by a 
chemiluminescence immunoassay (IMM), and a LC-MSMS method. A Deming regression 
gave comparable results for both methods for testosterone levels in the range 5–30 
nmol/L. We found a substantial higher mean level of testosterone (ANOVAs, p<0.0001), 
28.2% and 24.4% for IMM and LC-MSMS methods, respectively, in the oldest group (29 
years) compared to the 0 year group. The study demonstrated no impact of age, season or 
smoking. The higher mean levels of testosterone in the oldest groups indicated no 
degradation during storage, and the lower level in the fresh samples could suggest changes 
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in the background population during a time span of 29 years (1979 – 2008) among the 
men investigated in this study.  
Table 2. gives an overview of the studies, including the main results.
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8. General discussion  
The present work has addressed five main issues relevant to examination of archival serum 
samples: 1) differences induced by non-standardised preanalytical sample handling, 2) 
sublimation during storage, 3) component stability, 4) recovery of a degraded serum 
component (folate and folate derivatives) by a new assay, and 5) possible time trends in 
population levels of serum components. The stability studies have measured a number of 
components i.e. electrolytes, metabolites, enzymes, immunoglobulines, transport proteins,  
vitamins and hormones. The main results in paper I – III showed small or no changes in 
serum level for calcium, iron, creatinine, uric acid, albumin, AST, cystatin C, IgE, IgG, 
SHBG, and transferrin after 25 years of storage at –25 ºC. On the other hand, ferritin, ALT, 
CK, folate and folate-deratives were subjected to degradation, and the choice of analysing 
methods may be essential for the possibility to assess the original level of the component. For 
some enzymes the technique of measuring activity in archival samples should be replaced by 
measurements based on other characteristics e.g. mass determination by immunochemical 
techniques. Paper I examined some components (bilirubin and potassium) that illustrate some 
of the factors that contribute to preanalytical errors of which the information often is scarce. 
Increased component level due to water sublimation during storage can be revealed by 
measurement of sodium in a group of samples from different time points. Without this 
correction, small differences in component level may be masked or exaggerated. In paper IV 
we found the highest level of testosterone in the oldest samples which indicated a decreasing 
trend in the background population that may have masked a possible degradation. Besides the 
process of degradation there are three main topics to be discussed as to the validity of these 
results: the impact of sample handling, the study design in the present studies, and possible 
changes in the background population over time. 
 
8.1 Sample handling 
The Red Cross Blood Bank had collecting procedures that ensured a relatively similar sample 
handling over the years. Only the storage time of centrifugated whole blood samples (clotting 
time) before separation of the serum fraction may have differed, varying between 14 and 28 
hours. The lack of specific information on each sample is a weakness. To estimate the 
potential contribution from differences in clotting time on proteins, an experiment was 
performed and reported in paper II. Only minor changes were found for C-peptide, SHBG, 
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ferritin, ALT, AST, and CK with time, indicating that the delayed clotting times of 14, 22, 
and 28 hours had negligible impact on the serum proteins investigated. In paper III two 
paralleled 2008 samples were collected to investigate the impact of delayed clotting time on 
the folate metabolites. There was no statistically significant difference in folate concentration 
between the two parallels, which indicated that a difference in 6 hour of clotting time would 
not seriously affect the level of the different folate markers (data not published).  
 
The majority of the samples in the Janus Serum Bank has been collected during health 
examination surveys across the country and were subjected to delay in freezing of the serum 
fraction due to long-distance transport. Reduced quality may have occurred although the 
samples were transported on a cooling system that ensured a temperature between +3 ºC and 
+10ºC (2). Other studies, however, report no significant changes in level of common 
biological analytes (i.e. proteins and electrolytes) in rat serum under refrigeration for 7 days 
(50), and (i.e. cholesterol and enzymes) in human serum under refrigeration for 4 days 
(50;51).   
 
The observed differences in component levels over time may therefore have been caused by 
storage related changes. Degradation, conformational changes, molecular modifications or 
water sublimation may occur. The measuring methods can introduce errors that may appear as 
stability problems even in relatively fresh sample (52). Methods based on measurements of 
enzyme activity and the use of immunological assays with monoclonal antibodies, are 
especially vulnerable in this respect. In paper I and II we analysed our samples with routine 
instruments at a clinical hospital laboratory. The instruments had stable CVs over time and 
were run under strict quality assurance.  
 
The effect of the freeze and thaw procedures and repeated freeze and thaw cycles has not been 
addressed in the present thesis. In the Janus Serum Bank all samples retrieved for projects 
have to be thawed and refrozen at least once for aliquoting, and the procedure is to thaw slow 
at room temperature and freeze fast on dry ice. There are contradictory reports in the literature 
on the impact on antibodies, electrolytes, glucose, and enzymes (33;34;36-39;48) but we may 
assume that any influence of the freezing and thawing procedure would affect all samples in 
the same way. 
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8.2 Study design  
A cross-sectional design provides a snapshot of the outcome of interest at a particular point of 
time. When several cross-sectional sample collections are compared, people with some 
similar background characteristics are grouped although none is followed individually (53). In 
our design it may be difficult to distinguish between inter-individual differences and 
difference caused by storage. To overcome this, the sample size at each time point has to be 
large and sampled randomly from the population. To establish reference limits with 
confidence intervals it is recommended to use at least 120 subjects (44;54). We included 130 
individuals in each group to meet this requirement and still had the option to remove obvious 
outliers. We have found differences over time for several components. The questions arise 
whether these differences were statistically or clinically significant, and if the sample size was 
large enough. The interpretations are based on adequate statistical methods and on well 
established bias criteria. The number of individuals in each group is large enough to assure a 
proper determination of reference limits, but still there might be type I and II errors when 
comparing component levels.  
 
In the Janus Serum Bank blood donors have given samples repeatedly. Longitudinal time 
series was therefore an option that was discussed, the advantage being the possibility to 
follow the same person and describe the pattern of changes over time. Repeated observations 
at the individual level may offer an advantage over a cross-sectional design, as it may 
eliminate inter-individual biological variation, when an individual serves as his or her own 
control. The drawback using the longitudinal time series design may be the difficulties to 
obtain sufficiently large number of individuals with samples collected over large enough time 
span and at similar intervals. This type of study would still be affected by potential changes 
with increasing age (e.g. decreased hormone levels), and thereby confound the comparisons 
between samples with different storage times. Longitudinal sampling from the same 
individuals may also suffer from unregistered changes in diet, infections, or seasonal and 
cyclic variation. 
 
The use of samples from males only, may imply that some results are not representative for 
female donors. Males were chosen for all studies because they have less intra- and inter-
individual biological variation linked to sex hormones. Concerning the aspects of component 
stability in a biobank, it is unlikely that great difference between gender should exist. 
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The selection of components does not cover every aspect of quality in a biobank, but 
represented a broad spectrum of structurally different molecular component, many of them 
relevant to cancer research. However, it is impossible to generalise between components. 
Analogous components may decompose differently. In paper II we found that the two liver 
enzymes AST and ALT behaved very differently under storage; AST was relatively stable 
while ALT lost 73.4% of its activity after 25 years of storage. 
 
8.3 Lifestyle related changes in the background population 
 A historical biobank will also reflect time specific changes in the background population, and 
differences between old and new samples may therefore be caused by other than storage 
related factors. In paper IV we found a substantial higher testosterone level in the oldest 
samples that could not be explained by factors like age, diurnal or seasonal variations. 
Storage-related changes like degradation could have occurred, but are not very likely. The real 
difference in testosterone level would then have been even larger. Higher serum testosterone 
levels have been associated with smoking (55;56). Cotinine, the main metabolite of nicotine is 
believed to be a very stable compound (57), and can therefore serve as a measure of tobacco 
exposure (58;59). Figure 3 shows the results of cotinine measurement in serum from four 
groups of male donors in the Janus Serum Bank collected in 1979, 1991, 2004, and 2008. The 
difference in smoking pattern is in agreement with the change seen in the general Norwegian 
population (60). In the period 1972–2006 the proportion of male daily smokers in Norway 
was reduced from 61% to 27% (61). For men aged 45–54 years the proportion in 1979 and 
2008, was 46% and 26%, respectively, and corresponding for Janus 38.2% and 30%.  
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Figure 3. Exposure of tobacco in males from 4 collecting times in the Janus Serum Bank  
 
The prevalence of smoking has been reduced over the years, but we found no statistically 
significant correlation between cotinine and testosterone in our material. A number of acute 
and chronic changes in serum component concentrations, the chronic being relatively modest, 
are associated with smoking. Constant smoking may induce increased blood glucose, changes 
in leukocyte and erythrocyte counts, lipoproteins, activity of enzyme (angiotensin converting 
enzyme), hormone (prolactin), vitamins (pyridoxal phosphate, β-cartinoids), tumour marker 
(CEA), and heavy metals (copper, lead, cadmium and selenium) (62). Albumin was reported 
to increase by 3% in smokers. A correction of albumin levels in all groups according to 
cotinine levels may have increased the + 4.8% difference between the 1979 and 2008 samples 
(paper II) 
 
In the period 1973–2004 the alcohol consumption has changed in the Norwegian population 
by an increase in number of persons who consume alcohol relatively frequently, and the 
proportion that drink more than 10L pure ethanol per year has doubled (63). The chronic 
effects of alcohol abuse include increased serum activity of liver enzymes and triglycerides 
(62). The aminotransferases ALT and AST activities are increased due to direct liver toxic 
effects and was reported changed by 50% and 200%, respectively. The selection of 
individuals (blood donors) in our study, weigh against a high number of alcohol abusers, and 
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we have concluded that the trend of increased alcohol intake would not be expected to 
influence our results. 
 
Some other relatively large changes in lifestyle and socio-economic standards have also taken 
place in the Norwegian population during the last three decades. The most remarkable one is 
the prevalence of obesity. In the period 1963–95, the mean weight increased 5.6 kg for men 
and 1.3 kg for women. Body mass index (BMI) has increased steadily in men and the 
proportion with BMI above 30 kg/m2 was doubled during the period (64). A comparison study 
among men in Oslo aged 20-49 years between the time points 1972 and 2000, showed a 
change in mean BMI from 24.3 to 26.4 kg/m2 (65). We have no information on BMI for the 
blood donors, but we assume that the general change in BMI also may have affected the 
participants in our studies. Increased BMI is associated with reduced testosterone level 
(66;67) and may have contributed to the lower testosterone level in the 2008 group. 
 
Norwegian diet during the first decade after the Second World War was characterized by a 
high consumption of fat. In the period 1975–2000 the fat intake was reduced from 40 to 35 
energy percent (68). A drop in serum cholesterol level of 0.6–0.8 mmol/L (8.0–11.4%) in the 
Norwegian population between 1974 and 2002 has been demonstrated (69). Although 
cholesterol is a precursor of steroid hormones, the regulation of steroids are assumed to be 
largely independent of plasma cholesterol levels within the reference range. Dietary data for 
this period (70) show that the intake of vegetables, fruits, and juice has increased considerably 
and thus increased the consumption of vitamin C. Recently, vitamin and mineral enrichment 
of food in Norway has become allowed for several products, which might further increase the 
circulating level of these components. The use of dietary supplements (vitamins) is increasing 
in Sweden and Denmark (71;72), and probably in Norway as well, although exact data is 
lacking. We have investigated folate levels during the time period of 1979–2008. Folate 
degrades rapidly in serum and its instability makes it impossible to estimate any effect of 
increased intake of folate supplements. 
 
The alteration in the background population should be taken in to account when measuring 
components that may have been influenced by such changes. 
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9. Concluding remarks  
The quality of the samples is a very important aspect in all research projects that uses archival 
material. The aim in this work has been to investigate to what extent the samples in the Janus 
Serum Bank, reflect the biological, or biochemical situation in the individual at the time of 
sample collection. Different factors that may influence on the concentration of a sample 
component during collection, storage, and analysing have been discussed.  
 
Based on the results of this thesis it can be concluded: 
 Long-term stored serum samples seem to undergo a modest water sublimation that can 
be corrected for in research projects.  
 Some information on the variation of preanalytical sample handling can be assessed by 
analysing components that are influenced by clotting time, light exposure and 
haemolysis. In the absence of standardised sample handling, individual measurements 
of unstable parameters should be interpreted with caution. 
 Many proteins, e.g. immunoglobulins, that are often analysed in the Janus Serum 
Bank, are robust to long-term storage at –25 °C. 
 Choice of measurement technology may strongly influence the results for components 
that tend to degrade. 
 Changes in lifestyle over time in the background population may introduce 
confounding or bias in studies of archival biobank material. 
 
Despite a sub-optimal preanalytical sample-handling and a higher storage temperature 
compared to modern biobanks, the present thesis shows that the Janus serum samples are of 
adequate quality for a number of purposes. The combination of knowledge of component 
stability, an adequate design, and use of an optimal assay is essential. 
 
When examining components with unknown stability one is advised to run pilot studies to 
measure the levels of these in samples with different storage time and explore their 
distributions. This work advocates for the routine of proper matching of cases and controls 
according to time of blood draw, to minimize the impact of preanalytical handling, storage, 
and lifestyle effects.  
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